Articles

The decision to use adjuvant therapies in patients with renal-cell carcinoma (RCC) should be based on risk, patient goals, and shared decision-making. This topic was explored in a presentation by Matthew Zibelman, MD, Associate Professor, Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium. Read More ›

Young women with early-stage, hormone receptor–positive breast cancer attempting to become pregnant can safely pause endocrine therapy and resume it later, according to initial results from the international POSITIVE trial. Read More ›

A new report released by the American Cancer Society (ACS) shows that the incidence of colorectal cancer is rapidly increasing among younger individuals, and the disease is also being diagnosed at more advanced stages in people of all ages. Read More ›

Older Black and Hispanic patients with advanced cancer are less likely than White patients to receive opioid medications for pain relief in the last weeks of life, according to the results of a recent study published in the Journal of Clinical Oncology. Read More ›

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between January 27, 2023, and March 22, 2023. Read More ›

Biomarker testing is associated with improved overall survival in patients with advanced non–small-cell lung cancer, but disparities in access to testing persist. Read More ›

A review of treatments and clinical studies for non–small-cell lung cancer harboring the KRAS G12C mutation finds encouraging overall survival results. Read More ›

Palliative care is underused by Black and Hispanic/Latinx patients with advanced non–small-cell lung cancer. Read More ›

Evaluation of flat-dose nivolumab plus weight-based ipilimumab in patients with advanced non–small-cell lung cancer and poorer prognosis demonstrates efficacy with a tolerable safety profile. Read More ›

A recent review presents updated treatment strategies for patients with non–small-cell lung cancer harboring the KRAS G12C mutation. Read More ›